6.5 Toxicology Screening & Substance Use Assessment

6.5 Toxicology Screening & Substance Use Assessment

Quick Summary: The CP-C Detailed Content Outline lists toxicology screening as its own line item under Patient/Client Centric Care, and lists substance/drug abuse separately as a special situation under Community Based Needs. Community paramedics encounter substance use in three distinct forms: as the reason for the referral, as a hidden contributor to an apparently unrelated chronic disease failure, and as an unrecognized withdrawal syndrome in a recently discharged or newly homebound patient. All three demand structured screening rather than clinical impression.

Verbal Screening Instruments and Their Cut Points

Verbal screening precedes laboratory testing in nearly every community paramedicine encounter. It is faster, requires no consent complications, produces actionable severity information, and — unlike a urine screen — tells you about patterns of use rather than a snapshot of recent exposure.

[!TIP] CAGE versus AUDIT-C is a favorite discriminator. CAGE asks about ever — it identifies a lifetime history of problem drinking and can stay positive in someone sober for fifteen years. AUDIT-C asks about current consumption patterns and quantities. When a vignette asks you to quantify a patient's present hazardous drinking, AUDIT-C is the instrument. When the question is about a historical pattern, CAGE fits.

What a Urine Drug Screen Actually Tells You

This is the most misunderstood diagnostic in the community setting, and the exam tests it as a scope and interpretation problem rather than a procedural one.

Immunoassay Screening Versus Confirmatory Testing

[!WARNING] A presumptive positive is not evidence of drug use. Reporting an unconfirmed immunoassay result as fact — in documentation, to a family member, or to a housing or employment contact — is a clinical and legal error. The correct documentation language is "presumptive positive immunoassay screen for the opiate class; confirmatory testing pending."

Cross-Reactivity: The False Positives That Matter

The False Negatives That Matter More

A standard "five-panel" screen (amphetamines, cocaine metabolite, opiates, PCP, THC) is calibrated to a 1980s workplace-testing problem and misses most of what actually harms community paramedicine patients:

• Fentanyl and fentanyl analogs — structurally unrelated to morphine; require a dedicated fentanyl immunoassay strip. This is the single most consequential gap.
• Synthetic opioids such as nitazenes — missed by both opiate and fentanyl panels.
• Buprenorphine and methadone — each requires its own dedicated assay.
• Most benzodiazepines — many assays are calibrated to oxazepam and detect clonazepam, lorazepam, and alprazolam poorly or not at all.
• Gabapentin, pregabalin, kratom, xylazine, and synthetic cannabinoids — absent from routine panels entirely.

[!IMPORTANT] A negative screen never excludes intoxication or overdose. An unresponsive patient with pinpoint pupils and a respiratory rate of 6 has an opioid emergency regardless of what a urine cup says. Treat the patient, not the strip.

Detection Windows in Urine (Approximate)

Windows vary with dose, chronicity, hydration, renal function, body composition, and urine pH — which is exactly why a screen result must never be converted into a statement about when a patient used.

Specimen Integrity and Consent

• Consent. Testing requires the patient's informed consent within the program's medical direction. A urine drug screen collected without consent, or collected under the pretense of a different test, is a consent violation.
• Adulteration and validity checks. Temperature at collection (normally 90–100 °F within four minutes of voiding), creatinine, specific gravity, pH, and oxidant testing detect dilution or adulteration. Creatinine below 20 mg/dL with low specific gravity suggests dilution.
• Chain of custody. Any test with legal, custody, employment, or licensure consequence requires documented chain of custody: continuous accountability, tamper-evident seals applied in the patient's presence, and a signed transfer record at every handoff. Routine clinical monitoring does not require chain of custody — but if you cannot state at the outset which category applies, treat it as forensic.

Withdrawal Assessment: Scoring Severity, Not Impressions

Community paramedics frequently visit patients whose supply of alcohol, opioids, or benzodiazepines was interrupted by hospitalization, incarceration, loss of transportation, or loss of income.

Alcohol Withdrawal — CIWA-Ar

The Clinical Institute Withdrawal Assessment for Alcohol, Revised scores ten domains: nausea/vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, and orientation/clouding of sensorium.

Timelines matter: minor withdrawal begins 6–12 hours after the last drink; withdrawal seizures peak at 12–48 hours; alcoholic hallucinosis appears at 12–24 hours; and delirium tremens typically emerges at 48–96 hours with autonomic instability, profound confusion, and meaningful mortality if untreated.

[!CAUTION] Alcohol and benzodiazepine withdrawal can kill; opioid withdrawal is rarely lethal in an otherwise healthy adult. This asymmetry is a recurring exam discriminator. A patient with escalating tremor, diaphoresis, tachycardia, hypertension, and disorientation 60 hours after the last drink requires emergency transport — not a scheduled follow-up. In pregnancy, however, opioid withdrawal is dangerous to the fetus and also warrants urgent management.

Opioid Withdrawal — COWS

The Clinical Opiate Withdrawal Scale scores eleven items including resting pulse, sweating, restlessness, pupil size, bone or joint aches, rhinorrhea or lacrimation, gastrointestinal upset, tremor, yawning, anxiety or irritability, and gooseflesh skin.

COWS is also the gate for buprenorphine induction: starting buprenorphine before adequate withdrawal has developed (commonly a COWS of at least 8–12, per program protocol) can precipitate acute withdrawal because buprenorphine displaces full agonists from the receptor.

SBIRT and Harm Reduction in the Home

SBIRT — Screening, Brief Intervention, and Referral to Treatment — is the operational framework that converts a positive screen into an outcome:

1. Screening. Administer the validated instrument appropriate to the substance.
2. Brief Intervention. A 5- to 15-minute motivational conversation. Use the FRAMES elements — Feedback on personal risk, patient Responsibility for change, clear Advice, a Menu of options, clinician Empathy, and support for Self-efficacy. This pairs directly with the motivational interviewing skills covered elsewhere in this guide.
3. Referral to Treatment. For moderate-to-severe findings, warm-hand-off referral to addiction medicine, an opioid treatment program, or a certified buprenorphine prescriber.

Harm reduction interventions a community paramedic can deliver or arrange:

• Naloxone distribution and training for the patient and every household member, including how to recognize an overdose and that rescue breathing precedes and accompanies naloxone.
• Fentanyl test strips where legally available.
• Never-use-alone resources and overdose-response planning.
• Safe medication storage and disposal, which doubles as means-restriction counseling for co-occurring suicide risk.
• Wound assessment for injection-related infection — abscess, cellulitis, and the endocarditis red flags of fever with a new murmur, splinter hemorrhages, or embolic phenomena.
• Vaccination and testing linkage for hepatitis A/B, HIV, and hepatitis C.

The 42 CFR Part 2 Confidentiality Overlay

Substance use disorder treatment records created by federally assisted SUD programs carry protection stricter than HIPAA:

Practical translation for the community paramedic: information the patient tells you directly during your own assessment is your clinical record and follows normal rules. Records you obtain from an SUD treatment program carry Part 2 restrictions and cannot be forwarded onward without consent.

[!NOTE] Stigmatizing language is a documentation defect. Write "patient with opioid use disorder," not "addict" or "abuser"; write "presumptive positive immunoassay," not "dirty urine"; write "medication for opioid use disorder (MOUD)," not "replacement drugs." Documentation language measurably influences downstream clinician attitudes and the care the patient subsequently receives.

Worked Clinical Scenario: The Failing Heart Failure Plan

Presentation

A 61-year-old man with HFrEF has been enrolled in the CP program for eight weeks after his third readmission. His weights have been stable, his medication organizer is correct, and he can teach back his low-sodium plan. Yet his ankles are swelling again and he has missed two cardiology appointments. He appears diaphoretic and mildly tremulous at 9 a.m. His pulse is 104 and blood pressure 158/94, up from a baseline of 72 and 118/70.

Assessment

The CP asks the AUDIT-C questions. The patient reports drinking daily, "five or six" on a typical day, and six-or-more-drink occasions weekly — an AUDIT-C well above the positive threshold. He last drank about 40 hours ago because his ride to the store fell through. CIWA-Ar scoring returns 13.

Reasoning

• The adherence puzzle resolves. The care plan was not failing from knowledge deficit; alcohol was driving fluid load, contributing to cardiomyopathy, and consuming the transportation and money budget that appointments required.
• The acute issue outranks the chronic one. A CIWA-Ar of 13 at 40 hours after the last drink, with rising pulse and blood pressure, is moderate alcohol withdrawal on the trajectory toward the 48-to-96-hour delirium tremens window. This requires urgent medical evaluation now, not a scheduled follow-up.
• A urine drug screen is not the next step. It would not change the immediate management, would not detect alcohol usefully at 40 hours, and delays escalation.
• After stabilization, the CP delivers the brief intervention, arranges the warm hand-off to addiction medicine, and rebuilds the heart failure care plan around the newly identified driver — coordinating with cardiology and the PCP.

Common Exam Traps

1. Treating a presumptive positive as a definitive result. Confirmation by GC-MS or LC-MS/MS is required before any consequential use.
2. Trusting a negative five-panel. It does not exclude fentanyl, buprenorphine, methadone, most benzodiazepines, gabapentin, or xylazine.
3. Confusing CAGE with AUDIT-C. Lifetime history versus current consumption pattern.
4. Ranking opioid withdrawal above alcohol withdrawal in acuity. Alcohol and benzodiazepine withdrawal are the potentially lethal ones.
5. Forwarding SUD program records without consent. 42 CFR Part 2 restricts re-disclosure.
6. Collecting a screen without consent or a defined purpose, then discovering the result has legal consequences and no chain of custody.